| DB ID | MyCo_3791 |
| Title | Comparison of two β-D-glucan assays for detecting invasive fungal diseases in immunocompromised patients |
| Year | 2021 |
| PMID | 34082306 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | This study protocol was reviewed and approved by the Institutional Review Board of Severance Hospital in Seoul, Korea (IRB No. 1-2020-0021) and informed consent was waived. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Korea |
| Cohort | From December 2019 to January 2020, 272 serum samples from different patients referred to the laboratory for routine BDG measurement were tested. In total, 272 patients were identified during the study period. |
| Cohort No. | 272 |
| Age Group | Jan-92 |
| P Value | None |
| Sensitivity | 0.396 |
| Specificity | 0.835 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | Goldstream BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Goldstream BDG assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
